Efficacy and Safety of Immunotherapy in Head and Neck Tumors: A Systematic Review and Meta-Analysis of Clinical Outcomes and Survival Benefits - Summary - MDSpire
Advertisement
Efficacy and Safety of Immunotherapy in Head and Neck Tumors: A Systematic Review and Meta-Analysis of Clinical Outcomes and Survival Benefits
To assess the effectiveness and safety of immunotherapy for head and neck squamous cell carcinoma (HNSCC) and treatment success by biomarker status through a systematic review and meta-analysis.
Key Findings:
The clinical effectiveness assessment showed a combined rate of 0.16 (95% CI: 0.14–0.18) with considerable heterogeneity (I² = 81%).
Combination therapies achieved an improvement rate of 0.18 (95% CI: 0.15–0.22).
Dual/targeted immunotherapy showed superior performance with an improvement rate of 0.22 (95% CI: 0.19–0.24).
PD-L1-based outcomes had a pooled proportion of 0.17 (95% CI: 0.16–0.19) with moderate heterogeneity (I² = 66%).
Interpretation:
Immunotherapy provides moderate yet reliable results for HNSCC, with dual or targeted treatments showing the highest effectiveness. Randomized studies indicate strong treatment effects, while real-world data suggest variability and potential publication bias.
Limitations:
Inconsistent findings regarding effectiveness and safety across clinical trials and real-world settings.
Evidence of publication bias in effectiveness assessments.
Conclusion:
Immunotherapy represents a significant advancement in HNSCC treatment, with the PD-L1 biomarker being a useful, albeit inconsistent, predictor of response.
This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from April 16 - 30.
